The main infusion used for osteoporosis is zoledronic acid (brand name Reclast), given once a year through an IV. It belongs to a class of drugs called bisphosphonates, which slow bone loss and reduce fracture risk. A second IV bisphosphonate, ibandronate, is also approved but used less frequently. For most people searching this question, zoledronic acid is what their doctor is recommending or what they’ve heard about.
How the Infusion Works
Zoledronic acid targets the cells responsible for breaking down bone, called osteoclasts. Normally, your body is constantly rebuilding bone: old bone gets broken down while new bone forms. In osteoporosis, the breakdown outpaces the rebuilding. Zoledronic acid binds to areas of bone where turnover is highest and essentially shuts down the bone-dissolving cells. It blocks a key enzyme inside osteoclasts, which triggers those cells to die off. With fewer active bone-dissolving cells, bone density stabilizes and gradually improves.
There’s also some evidence that zoledronic acid may encourage bone-building cells to work more effectively, though its primary benefit comes from stopping excessive bone loss.
How Well It Reduces Fractures
In a clinical trial published in the New England Journal of Medicine, zoledronic acid reduced the risk of new spinal fractures by 67% compared to placebo over two years. The fracture rate was 1.6% in the treatment group versus 4.9% in the placebo group. Reductions in hip and other fractures were also observed, though the numbers in that particular trial were too small to reach statistical significance.
These results are consistent with broader bisphosphonate research showing meaningful protection at both the spine and hip, the two sites where osteoporotic fractures cause the most serious consequences.
What the Appointment Looks Like
The infusion itself takes a minimum of 15 minutes, though in practice most clinics run it over about 30 minutes. You’ll sit in a chair with an IV line, similar to getting fluids or a blood transfusion. The entire appointment, including check-in and a short monitoring period afterward, typically runs about an hour.
For osteoporosis treatment, zoledronic acid is given once every 12 months. For prevention (in people with thinning bones that haven’t yet reached the osteoporosis threshold), it may be given every two years. This once-yearly schedule is one of the main reasons people choose the infusion over daily or weekly oral pills.
Common Side Effects After Infusion
About half of patients experience flu-like symptoms after their first infusion. These typically start within one to three days and resolve within one to three days. The most common reactions include fever (affecting roughly 39% of first-time patients), muscle aches, joint pain, headache, chills, and general fatigue.
The good news: these reactions drop sharply with subsequent doses. After the second annual infusion, only about 12% of patients experience them. Your doctor may recommend taking acetaminophen or ibuprofen before or after the infusion to manage these symptoms.
Rare but Serious Risks
Two rare complications get the most attention with bisphosphonate therapy. Osteonecrosis of the jaw, where a section of jawbone loses blood supply and deteriorates, occurs in an estimated 1 in 10,000 to 1 in 100,000 osteoporosis patients on bisphosphonates. The risk increases slightly with longer treatment duration, rising from about 0.1% to 0.21% after four or more years of use.
Atypical femur fractures, unusual breaks in the thighbone that can occur with minimal trauma, happen at a rate of about 1.8 per 100,000 person-years during the first two years of treatment. That rate climbs with extended use, reaching up to 113 per 100,000 person-years after eight to ten years. This is one reason doctors sometimes recommend a “drug holiday” after three to five years of IV bisphosphonate therapy.
Preparation Before the Infusion
Your calcium levels must be normal before receiving zoledronic acid. Low calcium is a contraindication, meaning the infusion cannot be given until it’s corrected. Your doctor will likely check your blood calcium and vitamin D levels beforehand.
You’ll also need adequate calcium and vitamin D intake going forward. The FDA labeling recommends at least 1,200 mg of calcium and 800 to 1,000 IU of vitamin D daily, whether from food or supplements. People with conditions that affect mineral absorption, such as a history of parathyroid surgery or certain intestinal conditions, need those issues managed before starting treatment.
Who Qualifies for the Infusion
Osteoporosis is diagnosed when a bone density scan shows a T-score of -2.5 or lower at the spine, hip, or femoral neck. A T-score between -1.0 and -2.5 indicates osteopenia (thinning bones that haven’t reached the osteoporosis threshold). A fragility fracture, one caused by a fall from standing height or less, also counts as a clinical diagnosis of osteoporosis regardless of T-score.
Insurance coverage for IV bisphosphonates often requires that you’ve tried oral bisphosphonates first. Medicare, for example, covers zoledronic acid infusions when there’s documented intolerance or side effects from oral medications, problems with absorption, or when oral therapy has failed to improve or maintain bone density. People who can’t sit upright for 30 to 60 minutes after taking oral bisphosphonates (a dosing requirement for pills) also typically qualify.
Other Injectable Osteoporosis Treatments
Not every shot or injection for osteoporosis is technically an “infusion.” Two other injectable options work differently and are worth knowing about if you’re exploring your choices.
Denosumab is given as a small subcutaneous injection (under the skin, not into a vein) every six months. It targets the same bone-dissolving cells but through a different mechanism. It doesn’t carry the same risk of kidney problems associated with bisphosphonates and doesn’t cause the acute flu-like reaction. However, stopping denosumab can lead to a rapid rebound in bone loss, so it requires a transition plan if you discontinue it.
Romosozumab is a monthly subcutaneous injection given for 12 months only. It’s unique because it both stimulates new bone formation and reduces bone breakdown simultaneously. This dual action makes it the most aggressive bone-building option available. After the 12-month course, its effectiveness diminishes, so patients are typically transitioned to a bisphosphonate or denosumab to maintain the gains. Romosozumab is generally reserved for people at very high fracture risk.